Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term extension of apremilast in pediatric Behçet’s disease oral ulcers or juvenile psoriatic arthritis
2023-503433-21-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of apremilast in Behçet's disease (BD) and juvenile psoriatic arthritis (JPsA), sponsored by Amgen. Primary endpoints: Adverse events, Columbia-Suicide Severity Rating Scale (C-SSRS) and 3 more. Planned start Nov 2023; status: authorised.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2023-503433-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503433-21-00.